KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

被引：662

作者：

de Boer, Ian H. ^{[1
,2
]}

Rossing, Peter ^{[3
,4
,5
,6
]}

Caramori, M. Luiza ^{[7
,8
,9
,10
,11
]}

Chan, Juliana C. N. ^{[12
,13
]}

Heerspink, Hiddo J. L. ^{[14
,15
,16
,17
]}

Hurst, Clint ^{[18
]}

Khunti, Kamlesh ^{[19
,20
,21
,22
,23
,24
,25
]}

Liew, Adrian ^{[26
,27
,28
,29
,30
,31
,32
,33
,34
]}

Michos, Erin D. ^{[35
,36
,37
,38
,39
,40
,41
,42
,43
]}

Navaneethan, Sankar D. ^{[44
,45
,46
,47
]}

Olowu, Wasiu A. ^{[48
,49
]}

Sadusky, Tami ^{[50
,51
,52
,53
,54
,55
]}

Tandon, Nikhil ^{[56
,57
,58
,59
,60
,61
,62
,63
]}

Tuttle, Katherine R. ^{[64
,65
,66
,67
,68
,69
,70
,71
,72
,73
,74
]}

Wanner, Christoph ^{[75
,76
,77
,78
,79
]}

Wilkens, Katy G. ^{[80
,81
,82
]}

Zoungas, Sophia ^{[83
,84
,85
,86
,87
,88
]}

Jadoul, Michel ^{[89
,90
,91
,92
]}

Winkelmayer, Wolfgang C. ^{[92
,93
,94
,95
,96
,97
,98
,99
]}

Tonelli, Marcello A. ^{[100
,101
,102
,103
,104
,105
,106
]}

Craig, Jonathan C. ^{[107
,108
,109
,110
,111
,112
,113
,114
]}

Strippoli, Giovanni F. M. ^{[115
,116
]}

Tunnicliffe, David J. ^{[117
,118
,119
]}

Higgins, Gail Y. ^{[120
,121
,122
,123
]}

Natale, Patrizia ^{[124
,125
,126
]}

Cooper, Tess E. ^{[127
,128
]}

Willis, Narelle S. ^{[129
,130
]}

机构：

[1] Univ Washington, Epidemiol, Seattle, WA 98195 USA

[2] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA

[3] Steno Diabet Ctr Res Team, Copenhagen, Denmark

[4] Univ Copenhagen, Diabet Angiopathy, Copenhagen, Denmark

[5] European Diabet Nephropathy Study Grp, Copenhagen, Denmark

[6] Danish Natl Diabet Registry, Copenhagen, Denmark

[7] Univ Minnesota, Minneapolis, MN USA

[8] Univ Minnesota, Med Ctr, Joint Commiss Accredited Inpatient Diabet Serv, Minneapolis, MN 55455 USA

[9] NIH R01 Grant Study Protect Factors Diabet Kidney, Copenhagen, Denmark

[10] NKF Kidney Dis Outcomes Qual Initiat KDOQI Work G, Copenhagen, Denmark

[11] Diabet Nephropathy Subcomm ADA Sci Sess, Copenhagen, Denmark

[12] Chinese Univ Hong Kong, Med & Therapeut, Hong Kong, Peoples R China

[13] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China

[14] Univ Med Ctr Groningen, Clin Trials & Personalized Med, Groningen, Netherlands

[15] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[16] Univ New South Wales, Sydney, NSW, Australia

[17] George Inst Global Hlth, Sydney, NSW, Australia

[18] US Army, Washington, DC 20310 USA

[19] Univ Leicester, Primary Care Diabet & Vasc Med, Leicester, Leics, England

[20] UK Natl Inst Hlth Res NIHR Appl Res Collaborat AR, Leicester, Leics, England

[21] Ctr Ethn Hlth Res, Leicester, Leics, England

[22] Real World Evidence Unit, Leicester, Leics, England

[23] UK Govt Sci Advisory Grp Emergencies SAGE, Leicester, Leics, England

[24] SAGE Ethn Subpanel, Leicester, Leics, England

[25] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia

[26] Mt Elizabeth Novena Hosp, Kidney & Transplant Practice, Singapore, Singapore

[27] ISPD, Singapore, Singapore

[28] ISN, Execut Comm & Council, Singapore, Singapore

[29] ISN Oceania Southeast Asia Reg Board, Singapore, Singapore

[30] ISN End Stage Kidney Failure Strategy Dialysis Su, Singapore, Singapore

[31] ISN Renal Disaster Preparedness Working Grp, Singapore, Singapore

[32] ISN Dialysis Working Grp, Singapore, Singapore

[33] ISN Continuing Med Educ CME Comm, Singapore, Singapore

[34] Asia Pacific Soc Nephrol APSN CME Comm, Hong Kong, Peoples R China

[35] Johns Hopkins Univ, Div Cardiol, Med, Baltimore, MD USA

[36] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[37] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Womens Cardiovasc Hlth, Baltimore, MD USA

[38] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Prevent Cardiol, Baltimore, MD USA

[39] Board Directors Amer Soc Prevent Cardiol ASPC, Baltimore, MD USA

[40] Amer Coll Cardiol ACC Prevent Leadership Council, Washington, DC USA

[41] ACCs Clin Qual Approval Comm CPAC, Washington, DC USA

[42] AHA Funding Comm, Washington, DC USA

[43] Natl Inst Hlth Funded Multiethn Study Atheroscler, Bethesda, MD USA

[44] Baylor Coll Med, Nephrol Sect, Clin Res, Houston, TX 77030 USA

[45] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA

[46] NKF, New York, NY USA

[47] ASN, New York, NY USA

[48] OAUTHC, Dept Pediat, Pediat Nephrol & Hypertens Unit, Osun, Nigeria

[49] Obafemi Awolowo Univ, Dept Pediat & Child Hlth, Pediat Nephrol, Ife, Nigeria

[50] Univ Washington, Res Finance & Operat, Seattle, WA 98195 USA

来源：

KIDNEY INTERNATIONAL | 2022年 / 102卷 / 05期

关键词：

angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker; chronic kidney disease; dialysis; evidence-based; GLP-1 receptor agonist; glycemia; glycemic monitoring; glycemic targets; guideline; HbAlc; hemodialysis; KDIGO; lifestyle; metformin; models of care; nutrition; renin-angiotensin system; self-management; SGLT2; inhibitor; systematic review; teambased care; CONVERTING-ENZYME-INHIBITION; DIETARY-PROTEIN RESTRICTION; GLUCOSE COTRANSPORTER 2; GLOMERULAR-FILTRATION-RATE; INTENSIFIED MULTIFACTORIAL INTERVENTION; ESTABLISHED CARDIOVASCULAR-DISEASE; INSULIN-DEPENDENT DIABETICS; MODERATE SODIUM RESTRICTION; ASSESSING GLYCEMIC CONTROL; URINARY ALBUMIN EXCRETION;

D O I：

10.1016/j.kint.2022.06.008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained unchanged. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

引用

页码：S1 / S127

页数：127

共 467 条

[1] GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES - DESIGN OF A FEASIBILITY TRIAL
ABRAIRA, C
EMANUELE, N
COLWELL, J
HENDERSON, W
COMSTOCK, J
LEVIN, S
NUTTALL, F
SAWIN, C
[J]. DIABETES CARE, 1992, 15 (11) : 1560 - 1571
[2] VETERANS AFFAIRS COOPERATIVE STUDY ON GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES (VA CSDM) - RESULTS OF THE FEASIBILITY TRIAL
ABRAIRA, C
COLWELL, JA
NUTTALL, FQ
SAWIN, CT
NAGEL, NJ
COMSTOCK, JP
EMANUELE, NV
LEVIN, SR
HENDERSON, W
LEE, HS
[J]. DIABETES CARE, 1995, 18 (08) : 1113 - 1123
[3] Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Afkarian, Maryam
Zelnick, Leila R.
Hall, Yoshio N.
Heagerty, Patrick J.
Tuttle, Katherine
Weiss, Noel S.
de Boer, Ian H.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (06): : 602 - 610
[4] Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Afshin, Ashkan
Sur, Patrick John
Fay, Kairsten A.
Cornaby, Leslie
Ferrara, Giannina
Salama, Joseph S.
Mullany, Erin C.
Abate, Kalkidan Hassen
Abbafati, Cristiana
Abebe, Zegeye
Afarideh, Mohsen
Aggarwal, Anju
Agrawal, Sutapa
Akinyemiju, Tomi
Alahdab, Fares
Bacha, Umar
Bachman, Victoria F.
Badali, Hamid
Badawi, Alaa
Bensenor, Isabela M.
Bernabe, Eduardo
Biryukov, Stan H.
Biadgilign, Sibhatu Kassa K.
Cahill, Leah E.
Carrero, Juan J.
Cercy, Kelly M.
Dandona, Lalit
Dandona, Rakhi
Anh Kim Dang
Degefa, Meaza Girma
Zaki, Maysaa El Sayed
Esteghamati, Alireza
Esteghamati, Sadaf
Fanzo, Jessica
Farinha, Carla Sofia E. Sa
Farvid, Maryam S.
Farzadfar, Farshad
Feigin, Valery L.
Fernandes, Joao C.
Flor, Luisa Sorio
Foigt, Nataliya A.
Forouzanfar, Mohammad H.
Ganji, Morsaleh
Geleijnse, Johanna M.
Gillum, Richard F.
Goulart, Alessandra C.
Grosso, Giuseppe
Guessous, Idris
Hamidi, Samer
Hankey, Graeme J.
[J]. LANCET, 2019, 393 (10184) : 1958 - 1972
[5] Physical Activity and Hemodynamic Reactivity in Chronic Kidney Disease
Agarwal, Rajiv
Light, Robert P.
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (06): : 1660 - 1668
[6] Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, Rajiv
Kolkhof, Peter
Bakris, George
Bauersachs, Johann
Haller, Hermann
Wada, Takashi
Zannad, Faiez
[J]. EUROPEAN HEART JOURNAL, 2021, 42 (02) : 152 - 161
[7] Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
Agarwal, Rajiv
Joseph, Amer
Anker, Stefan D.
Filippatos, Gerasimos
Rossing, Peter
Ruilope, Luis M.
Pitt, Bertram
Kolkhof, Peter
Scott, Charlie
Lawatscheck, Robert
Wilson, Daniel J.
Bakris, George L.
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (01): : 225 - 237
[8] Robust copy-move forgery detection using modified superpixel based FCM clustering with emperor penguin optimization and block feature matching
Agarwal, Ritu
Verma, Om Prakash
[J]. EVOLVING SYSTEMS, 2022, 13 (01) : 27 - 41
[9] Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria
Ahmad, J
Siddiqui, MA
Ahmad, H
[J]. DIABETES CARE, 1997, 20 (10) : 1576 - 1581
[10] Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects
Ahmad, J
Shafique, S
Abidi, SMA
Parwez, I
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 60 (02) : 131 - 138

← 1 2 3 4 5 6 7 8 9 10 →